OVARIAN CANCER SYMPOSIUM

Transcription

1 OVARIAN CANCER SYMPOSIUM Immunotherapy and targeted therapy in ovarian cancer supported by in alliance with 5 MAY 2018 MELBOURNE EVENT PROGRAM 9:30am 10:00am Registration Welcome: Jane Hill (OCA CEO) SESSION ONE: PARP inhibitors and Clinical registry (Chair: Prof Anna DeFazio) 10.10am 10.40am 11.00am 11.20am 11.30am Keynote: Professor Ursula Matulonis PARP inhibitors: opportunities, challenges and new directions A/Prof Linda Mileshkin Combining PARP inhibitors and immunotherapy to treat ovarian cancer Prof John Zalcberg Ovarian Cancer Clinical Quality Registry progress and challenges Morning tea SESSION TWO: Acquired resistance (Chair: Prof David Bowtell) 11.50am 12.10pm 12.30pm 12.50pm 1.00pm Dr Liz Christie Acquired chemotherapy resistance in high-grade serous ovarian cancer Dr Peter Savas Perspectives from breast cancer - immunotherapy and precision oncology Dr Olga Kondrashova Unraveling novel mechanisms of resistance and sensitivity to PARP inhibition in ovarian carcinoma Lunch SESSION THREE: Immunotherapy (Chair: Dr Tarek Meniawy) 1.40pm 2.00pm 2.20pm 2.40pm 2.50pm Dr Dale Garsed Surviving ovarian cancer: the role of the immune response Dr George Au-Yeung Immunotherapy combinations in high-grade serous ovarian cancer Dr Tarek Meniawy Immunotherapy for ovarian cancer: are we there yet? Afternoon tea SESSION FOUR (Chair: Prof Anna defazio) 3.05am 3.20pm 3.55pm 4.00pm A/Prof Clare Scott The role of PARP inhibitors in non-brca ovarian cancer Tumour Board Discussion Prof Ursula Matulonis - Medical oncologist A/Prof Alison Brand - Gynaecological oncologist Prof Anna defazio - Cancer researcher A/Prof Lyndal Anderson - Pathologist Dr Tania Moujaber - Medical oncologist Closing comments: Jane Hill (OCA CEO) Event close

2 GUEST SPEAKER PROFILES Keynote Speaker Professor Ursula A. Matulonis MD, BSc, FRCP Guest Speakers Professor of Medicine, Harvard Medical School, Director and Disease Center Leader of the Gynecologic Oncology Program, Dana-Farber Cancer Institute Professor Ursula Matulonis is a Professor of Medicine at Harvard Medical School and Director and Disease Center Leader of the gynecologic oncology program at the Dana-Farber Cancer Institute. She is the first recipient of the Brock-Wilson Family Chair at Dana-Farber. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer. Professor Matulonis has led several PARP inhibitor, antiangiogenic agent and combination trials for ovarian cancer in the United States. Prof Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline Committee for ovarian cancer, the Massachusetts Ovarian Cancer Task Force, the NRG Ovarian Committee, and the Scientific Advisory Board for the Ovarian Cancer Research Foundation Alliance and the Clearity Foundation. She received the Dennis Thompson Compassionate Care Scholar Award, the Lee M. Nadler Extra Mile Award and the Zakim Award for patient advocacy. After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA. Professor Anna defazio BSc (Hons), PhD Sydney West Chair of Translational Cancer Research, University of Sydney, Westmead Institute for Medical Research and Department of Gynaecological Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital (Sydney) Professor Anna defazio is the Sydney- West Chair in Translational Cancer Research, University of Sydney at Westmead Hospital. She is the co-deputy Director of the Sydney-West Translational Cancer Research Centre and heads the Gynaecological Oncology Research Group in the Centre for Cancer Research, Westmead Institute for Medical Research. Prof defazio has a long-standing commitment to translational research with an emphasis on improving treatment outcome for women with ovarian cancer. The focus of her research is on understanding the clinico-genomic parameters that underlie response and resistance to systemic therapy. Prof defazio completed her PhD at the Ludwig Institute for Cancer Research, University of Sydney and undertook post-doctoral studies at the Garvan Institute before moving to Westmead to establish a new program of research into ovarian cancer. Prof defazio is the lead investigator on INOVATe (Individualised Ovarian Cancer Treatment through Integration of Genomic Pathology into Multidisciplinary Care), a NSW-wide program focused on precision medicine and ovarian cancer clinical trials. She is also an investigator on a number of national and international collaborative studies including AOCS (Australian Ovarian Cancer Study), OPAL (Ovarian cancer, Prognosis and Lifestyle), and MOCOG, an international study focused on long-term survival following a diagnosis of ovarian cancer. Professor John R Zalcberg OAM MB BS, PhD, FRACP, FRACMA, FAH MS, FAICD Chair of Oncology, Alfred Health and Head, Cancer Research Program, School of Public Health and Preventive Medicine, Monash University Professor Zalcberg is the inaugural Tony Charlton Chair of Oncology at Alfred Health and Head of the Cancer Research Program in the School of Public Health and Preventive Medicine at Monash University. He currently oversees the establishment and activities of clinical quality registries across various tumour types. He was previously the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne from 1997 to 2014 as well as their Chief Medical Officer from 2007 to He is the current Chair of the Australian Clinical Trials Alliance and serves on the Board of the Australian Red Cross Blood Service. A co-founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he is immediate past Chair of the Board of AGITG after serving in this role for over 15 years and a past Board Member of Cancer Trials Australia and Co-Chair of the Cancer Drugs Alliance. Past positions also include Board Member of the NSW Cancer Institute, President of the Clinical Oncological Society of Australia, and a past Member of the Consultative Council of the Victorian Cancer Agency (VCA). He received a Medal of the Order of Australia Award (OAM), the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia and the 2015 Tom Reeve Award for outstanding contribution to cancer care from the Clinical Oncological Society of Australia (COSA). In 2014 the AGITG announced the annual John Zalcberg OAM Award for Excellence in Australasian Gastro-Intestinal Trials Group (AGITG) Research in his honour. He has over 280 articles published in peer-reviewed journals and has received funding in excess of $54million over the course of his career.

3 Professor David Bowtell B AnimSc, BVSc (Hons), PhD Head, Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, Melbourne Professor Bowtell is Head of the Cancer Genomics and Genetics Program at the Peter MacCallum Cancer Centre. He is also a Visiting Professor at Dana-Farber Cancer Institute, Boston, and was Director of Research at the Peter MacCallum Cancer Centre for a decade from Professor Bowtell has an extensive background in human cancer genomics. He is Principal Investigator for the Australian Ovarian Cancer Study (AOCS), one of the largest population-based cohort studies of ovarian cancer in the world involving over 3000 women, and CASCADE, a rapid autopsy study. Professor Bowtell s research has focused on the classification of ovarian cancer, mechanisms of primary and acquired drug resistance, and the role of BRCA1/2 and other HR pathway mutations in ovarian cancer risk and therapeutic response. His work is part of the International Cancer Genome Consortium. Associate Professor Lyndal Anderson MBBS, BMedSci, FRCPA, FIAC, MHM, MPhil, GradDipCrim, GradCertClinEduc. Senior Staff Specialist, Department of Tissue Pathologiy and Diagnostic Oncology, Royal Prince Alfred Hospital Associate Professor Lyndal Anderson is a medical graduate of the University of Tasmania and commenced Pathology training in England in In Australia she trained at St Vincent s Hospital Sydney and the Royal Prince Alfred Hospital before completing her Fellowship from the Royal College of Pathologists of Australasia in She completed a Master of Philosophy in Gynaecological Pathology with The University of Sydney in 2011 and a Masters of Health Management with The University of New South Wales in Her primary interests include Gynaecological Pathology and Cytopathology. Associate Professor Anderson is a Senior Staff Specialist at Royal Prince Alfred Hospital, an Associate Professor at Western Sydney University and Senior Clinical Lecturer at The University of Sydney. She is on the National Cervical Screening Renewal Program Project Steering Committee, the Cancer Council of Australia Working Party for the Guidelines for Prevention of Cervical Cancer and the working party for cervical biopsy reporting guidelines for the Royal College of Pathologists of Australasia. She is the current National representative for Public Pathology Australia and a member of the Research Advisory Committee for ANZGOG. She is the current Vice President for the Australian Society of Cytology. Present interests include research collaborations with the Australian Ovarian Cancer Study Group, Australian Cervical Cancer Typing Study Group and commitment to medical education through registrar teaching and completion of a Graduate Certificate of Clinical Education in In 2015 she was awarded a Women s Leadership Australia Accelerated Leadership Performance Program Scholarship to the Australian School of Applied Management. Associate Professor Alison Brand MD MMED FRCS(C) FRANZGOG CGO Director Gynaecological Oncology, Westmead Hospital Associate Professor Alison Brand is a Clinical Associate Professor at the University of Sydney and Director of the Department Gynaecological Oncology at Westmead Hospital, Sydney. She has recently stepped down after 6 years as Chair of the Australian and New Zealand Gynaecological Oncology Group (ANZGOG). A/Prof Brand has held a number of advisory and/or board positions with national and international gynaecological cancer organisations, including Cancer Australia, the Clinical Oncology Society of Australia and the Gynaecological Cancer Intergroup (GCIG). She has a particular interest in quality assurance and is currently Co-Chair of the GCIG Quality Assurance Working Group. She is the Australian PI for the STATEC surgical trial. Associate Professor Linda Mileshkin MBBS, MD, FRACP, MBioeth (Mon) Deputy Director of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne Associate Professor Linda Mileshkin is a medical oncologist and a clinical researcher with a particular interest in the treatment of lung and gynaecological cancers, as well as the supportive care of people affected by cancer. She also runs Australia s only specialist clinic dedicated to the care of people affected by Cancer of Unknown Primary (CUP). She consults both at the Peter MacCallum Cancer Centre in Parkville and at the Mercy Hospital for Women in Heidelberg. Subsequent to training in medical oncology, she has completed a Masters of Bioethics as well as a translational research fellowship examining the role of predictive and prognostic factors in patients treated with thalidomide for multiple myeloma. Subsequently she has continued to expand her research portfolio and is currently involved in multiple clinical research projects involving people with gynaecological and lung cancers, plus carcinoma of unknown primary (CUP), as well as phase I trials in multiple tumour types. Her current research focuses on early and late phase clinical trials testing novel therapies for cancer and the supportive care of people affected by cancer. She is the international study chair for an international Australia-led government funded phase 3 trial of adjuvant therapy in locally advanced cervical cancer, as well as the principal investigator for multiple local and national trials. She is the clinical trials lead for Gynae-Oncology in the Parkville Cancer Clinical Trials Unit and is the Chair of the Gynaecological Tumour Group for Cancer Trials Australia as well as a core member of the Peter MacCallum Cancer Centre Department for Cancer Experiences Research. She is also very involved in the Australia New Zealand Gynaecological Oncology Group (ANZGOG) as a member of the board and the Research Advisory Committee.

4 Associate Professor Clare Scott MBBS PhD FRACP Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Royal Women s Hospital. Head of the Ovarian and Rare Cancers Laboratory, Walter and Eliza Hall Institute of Medical Research Associate Professor Clare Scott is a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre and the Royal Melbourne and Royal Women s Hospitals and is Head of the Ovarian and Rare Cancers Laboratory at the Walter and Eliza Hall Institute of Medical Research. She has 20 years experience in treating breast and ovarian cancer and in clinical cancer genetics in Familial Cancer Clinics. Clare has been Principal Investigator for more than ten ovarian cancer clinical trials of targeted therapy leading to high impact publications. In the lab, Clare has developed new ovarian cancer pre-clinical models and is using genomics to study targeted drug combinations to combat drug resistance. Clare has established a rare cancer research program to improve access to targeted treatments for patients diagnosed with a rare cancer. Clare was awarded the Sir Edward Dunlop Cancer Research Fellowship from Cancer Council Victoria (2012) and a Clinical Research Fellowship from the Victorian Cancer Agency (2017). Dr George Au-Yeung MBBS FRACP PhD Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne Dr George Au-Yeung is a clinicianresearcher at the Peter MacCallum Cancer Centre, and has a research interest in immunology and molecular biology of ovarian cancer. He completed his PhD in Professor David Bowtell s laboratory, investigating novel therapeutic strategies for Cyclin E1 amplified high grade serous ovarian cancer, a particular subset of ovarian cancers that behave aggressively and lack treatment options. He is now a full-time medical oncologist, working across the Gynae-Oncology and Melanoma services. He was also a past member of the MOGA Executive, and a current member of the RACP Advanced Trainee Committee for Medical Oncology. Dr Tarek Meniawy MBBS FRACP PhD Medical Oncologist, Sir Charles Gairdner Hospital. Clinical Senior Lecturer, University of Western Australia Tarek Meniawy is a Medical Oncologist who sub-specialises in gynaecological cancers as well as melanoma or the skin. He holds a Consultant appointments at Sir Charles Gairdner Hospital, the King Edward Memorial Hospital, as well St John of God Subiaco Hospital. He is also a Clinical Senior Lecturer at the University of Western Australia. Tarek completed his medical degree at Cairo University, before undertaking postgraduate physician training at the Princess Alexandra Hospital in Brisbane. He then undertook further training in Medical Oncology at Royal Perth Hospital and Sir Charles Gairdner Hospital, before being awarded the Fellowship of the Royal Australasian College of Physicians in More recently, he has been awarded a Doctor of Philosophy (PhD) degree by the University of Western Australia, where he studied the effects of anti-cancer therapies on the immune system. Dr Meniawy has a keen interest in teaching and research, particularly in the field of cancer immunology and immunotherapy. He is actively involved in clinical trials, acting as a Principal Investigator or co-investigator of more than 20 active studies, including early trials of novel targeted therapies and immunotherapies in different tumour types, large multi-national trials in gynaecological cancers and melanoma, as well as grant-funded, investigator-initiated research. He is a member of the WA Gynaecological Cancer Service as well as the WA Melanoma Advisory Service. He is also a member of several national and international professional organisations, including the American Society of Clinical Oncology, the International Gynaecological Cancer Society, the Medical Oncology Group of Australia, and the Clinical Oncology Society of Australia. He is also an active member of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG). His work was published in a number of original articles in peer-reviewed journals, book chapters and conference papers, and has presented regularly at local, national and international conferences. Dr Dale Garsed PhD Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, Melbourne Dr Dale Garsed completed his PhD at the Peter MacCallum Cancer Centre and University of Melbourne, studying the structure, evolution and molecular drivers of liposarcoma chromosomes. In 2013, began his postdoctoral training in the Cancer Genomics and Genetics laboratory, also at the Peter MacCallum Cancer Centre, under the mentorship of Prof David Bowtell. The focus of the Bowtell lab is genomic classification of ovarian cancer, using a combination of molecular profiling and functional genomics approaches with a particular interest in mechanisms of chemotherapy sensitivity and resistance. Dale is currently investigating the molecular basis of exceptional responses to chemotherapy in women who are long-term survivors of ovarian cancer.

5 Dr Liz Christie PhD Cancer Genetics and Genomics Laboratory, Peter MacCallum Cancer Centre, Melbourne Dr Liz Christie joined the Peter MacCallum Cancer Centre as a postdoctoral researcher in the Cancer Genetics and Genomics lab in Liz completed her PhD at the Ludwig Institute for Cancer Research and the University of Melbourne, studying developmental biology and its links to cancer using zebrafish. Her current work with Professor David Bowtell focuses on understanding the genomic mechanisms underlying chemotherapy resistance in ovarian cancer, as well as utilising circulating tumour DNA as a biomarker. Dr Peter Savas MBBS FRACP Medical oncologist, Peter MacCallum Cancer Centre, Melbourne Dr Peter Savas is a medical oncologist currently completing a PhD in breast cancer genomics at the Peter MacCallum Cancer Centre. His work is focussed on understanding cancer heterogeneity and implementation of a pilot study of personalised medicine for advanced breast cancer. He has applied genomic technologies to studying the evolution of breast cancer into advanced, lethal disease. He has also studied the immune microenvironment of breast cancer with a focus on novel T cell populations identified using single cell sequencing. Dr Tania Moujaber B Med Sci, MBBS (Hons), FRACP Medical Oncology Fellow, Crown Princess Mary Cancer Centre, Westmead Hospital. PhD Candidate, University of Sydney, Westmead Institute for Medical Research Dr Tania Moujaber is a Medical Oncologist and completed her clinical training in 2015 at the Crown Princess Mary Cancer Centre, in Sydney with an interest in the treatment of women with gynaecological and breast cancer. Tania has a focus on translational research and is currently undertaking a PhD with Professor Anna defazio s Gynaecological Oncology laboratory group at the Westmead Institute of Medical Research. Her research is focused on investigating the molecular pathways that underpin the malignant phenotype in low-grade serous ovarian cancer and identifying potential treatment targets to improve response to treatment and clinical outcomes in women with this chemo-resistant ovarian cancer subtype. Dr Olga Kondrashova PhD Post Doctoral Scientist, The Walter and Eliza Hall Institute of Medical Research Dr Olga Kondrashova earned her Bachelor of Forensic Science (Hons) at Bond University, Gold Coast in She then changed her research focus to oncology, receiving her PhD on molecular profiling of ovarian cancer from the University of Melbourne in As part of her PhD she was involved in the establishment of the ALLOCATE project, a pilot study demonstrating feasibility of genomic profiling patients with recurrent ovarian cancer with the aim of allocating patients to targeted therapies. Following this, she joined A. Prof. Clare Scott s lab at the Walter and Eliza Hall Institute undertaking her postdoctoral studies on mechanisms of PARP inhibitor sensitivity and resistance in ovarian carcinomas.